대화제약

067080KOSDAQ

52.8 / 100

Reference Date: 2026-09-08

Financial Score14.0 / 40

News Sentiment18.8 / 25

Momentum10.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Surged 16.5% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Dae Hwa Pharmaceutical primarily engages in the manufacturing and sales of pharmaceuticals, medical devices, and raw materials, supplying a wide range of products such as antibiotics and pain relievers both domestically and internationally. The company has expanded its overseas markets through partnerships with German and Chinese firms and focuses on R&D investment for new drug development.

Number of Employees

369people

Average Salary

48.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

117.13Industry Average 15.000.0Point

7.8x industry avg (risky)

PBR

2.59Industry Average 1.200.0Point

2.2x industry avg (risky)

ROE

3.00Industry Average 8.001.0Point

Well below industry avg

Debt Ratio

12.94Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20255.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲0.7% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲94.5% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 1.1% (improving, 3yr)

Detailed News Sentiment

4 totalPositive 3Neutral 0Negative 1Average Sentiment Score 75

Positive
[바이오스냅] 대웅제약, '나보타' 협력사와 마케팅 전략 공유
대웅제약의 주요 제품 나보타의 글로벌 마케팅 전략 강화로 인해 긍정적인 시장 반응 예상.
Negative
높아진 R&D 문턱, 낮아진 약가…중소 제약사 ‘이중고’
강화된 혁신형 제약기업 인증 요건으로 중소 제약사인 대화제약의 경쟁력이 약화될 우려가 있다.
Positive
국제약품, '인다파미드 고혈압 3제 복합제' 시장 가세
대화제약의 새로운 고혈압 치료제 출시로 인해 순환기 치료제 시장에서의 경쟁력 강화가 예상됩니다.

Detailed Momentum

52-week position3.0Point

52w lower range (20%)

Current 11,010Won52-week high 23,30052-week low 7,870

1-month return6.0Point

1m +16.51% (strong rise)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral단일판매ㆍ공급계약해지2026-09-07
Neutral주식등의대량보유상황보고서(일반)2026-08-20